Evidence-grounded replies only

Ask the Founder

Real questions. Answers grounded in the evidence.

Last updated: May 2026

From your question to a published answer

A transparent, evidence-first process — no personal medical advice, no speculation.

01
Submit your question

Use the form below. Include as much context as you like. No name required.

02
Weekly review

The Founder reviews questions weekly, prioritizing those most relevant to the EBL evidence base and the broadest audience.

03
Answers published here

Selected answers appear in the section below — no names, no personal medical advice, always citation-backed.

Important: This is an educational resource. Answers do not constitute medical advice. Educational use only. Do not start, stop, or change medications, supplements, or treatment based on these responses.

Ask the Founder

All questions reviewed. Selected answers published publicly without identifying information.

Selected Q&A

A growing archive of evidence-grounded answers. Names never published.

What's the single highest-impact supplement for someone over 50 with no known deficiencies?

Based on the breadth of human trial data, Magnesium Glycinate is the most broadly evidence-supported starting point. Roughly 45% of US adults are deficient (NHANES), and adequacy underpins 300+ enzymatic reactions including ATP synthesis, DNA repair, and cardiovascular function. Omega-3 (EPA+DHA) is a close second given the cardiovascular mortality data.

Is creatine safe for long-term use in older adults?

Yes — the evidence is reassuring. A 2021 meta-analysis in the Journal of the International Society of Sports Nutrition found no adverse effects on kidney function in healthy adults with long-term use at 3–5g/day. Creatine is one of the most studied supplements in existence with 500+ peer-reviewed trials.

Do I need to cycle NAD+ precursors or can I take them continuously?

The cycling question remains open in the literature. Current human trials (Yoshino 2021 in Science, Martens 2023 in Nature Aging) do not show evidence of tolerance or diminishing returns with continuous NMN/NR use. That said, some practitioners prefer an "on/off" approach out of caution — there's no human data supporting this as necessary.